# A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors

> **NCT04413227** · PHASE1 · UNKNOWN · sponsor: **Jiangsu Simcere Pharmaceutical Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- NSCLC
- Solid Tumor

## Interventions

- **DRUG:** Pegylated Recombinant Human Endostatin（PEG-ENDO）

## Key facts

- **NCT ID:** NCT04413227
- **Lead sponsor:** Jiangsu Simcere Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-02
- **Primary completion:** 2021-05-31
- **Final completion:** 2021-09-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04413227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04413227, "A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04413227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*